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Abstract
Purpose of review—Hematopoietic stem/progenitor cell fate decision during hematopoiesis is 
regulated by intracellular and extracellular signals such as transcription factors, growth factors, 
and cell-to-cell interactions. In this review we explore the function of DEK, a nuclear 
phosphoprotein, on gene regulation. We also examine how DEK is secreted and internalized by 
cells, and discuss how both endogenous and extracellular DEK regulates hematopoiesis. Finally, 
we explore what currently is known about the regulation of DEK during inflammation.
Recent findings—DEK negatively regulates the proliferation of early myeloid progenitor cells 
but has a positive effect on the differentiation of mature myeloid cells. Inflammation regulates 
intracellular DEK concentrations with inflammatory stimuli enhancing DEK expression. 
Inflammation-induced NF-κB activation is regulated by DEK, resulting in changes in the 
production of other inflammatory molecules such as IL-8. Inflammatory stimuli (i.e. DEK) in turn 
regulates DEK secretion by cells of hematopoietic origin. However, how inflammation-induced 
expression and secretion of DEK regulates hematopoiesis remains unknown.
Summary—Understanding how DEK regulates hematopoiesis under both homeostatic and 
inflammatory conditions may lead to a better understanding of the biology of HSCs and HPCs. 
Furthering our knowledge of the regulation of hematopoiesis will ultimately lead to new 
therapeutics that may increase the efficacy of hematopoietic stem cell transplantation.
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Introduction
All cellular blood forming elements mature from the hematopoietic stem (HSC) and 
progenitor (HPC) cell populations. HSC and HPCs from the bone marrow, mobilized to the 
peripheral blood, or found in umbilical cord blood have been used in hematopoietic stem 
cell transplantation (HSCT) for the treatment of malignant and non-malignant diseases. 
Understanding the elements that regulate how these cell populations are maintained, 
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differentiate, and mature ultimately will lead to improved methods of HSCT allowing for a 
more efficient and effective means to treat disease. One possible factor that influences HSC 
and HPC cell fate is the nuclear phosphoprotein DEK. DEK was originally discovered as 
part of the fusion protein DEK-NUP214 (i.e. DEK-CAN), a result of a t(6;9) chromosome 
translocation in a subset of patients with acute myelogenous leukemia [1–4*], and as an 
oncoprotein in various neoplasms including melanoma [5–7*], breast cancer [8], 
glioblastoma [9], hepatocellular carcinoma [10, 11*], retinoblastoma [12, 13], gastric 
adenocarcinoma [14*], non-small cell lung cancer [15*], pancreatic ductal adenocarcinoma 
[16*], and bladder cancer [17]. DEK was found to be a regulator of hematopoiesis 
controlling HSC and HPC numbers/fate decision [18, 19]. These findings were further 
supported by the fact that DEK plays an important role in mediating the activation of the 
granulocyte-colony stimulating factor receptor 3 (GCSFR3) promoter which regulates 
myeloid cell differentiation [20]. Even though many have explored the role of DEK under 
malignant conditions, little is known how DEK functions to regulate HSCs, HPCs, and 
hematopoiesis. In this review we will explore possible mechanisms how both intracellular 
and extracellular DEK may regulate hematopoiesis under homeostatic and stress/
inflammatory conditions.
Intracellular and Extracellular DEK Functions
Intracellular/Endogenous DEK Function
The DEK gene encodes a conserved and structurally unique DNA-binding nuclear protein 
expressed in higher eukaryote cells and is the only known member of its protein class [21]. 
Although DEK bears little resemblance to other proteins, DEK does contain a conserved 
region called the Saf/Actinus/PARP-box (SAP-box) that has a helix-turn-helix motif that 
binds to DNA [22] further facilitated by a second DNA binding structure found in the C-
terminal end of the protein [22, 23**]. There is some debate on how DEK recognizes where 
to bind to DNA. Either DEK functions by binding to specific DNA structures or in a 
sequence-dependent manner [23**] since DEK both accumulates onto specific chromatin 
structures (such as four-way DNA junctions [24]) and to sequence-specific areas (such as 
TG-rich peri-ets sites of HIV-2 enhancer regions [25]). However, there remains some 
controversy on whether DEK recognizes specific DNA sequences as DEK has been shown 
to non-discriminately bind to DNA of various sequences in the absence of other proteins [26, 
27].
DEK is involved in various nuclear processes including transcription, DNA replication and 
DNA repair implicating a role for DEK in gene regulation. However, whether DEK 
promotes or represses gene expression remains controversial. DEK is associated with both 
activating (e.g. H3K4me2/3) and repressive (e.g. H3K9me3) histone modifications [28, 29]. 
Immunofluorescent imaging studies showed that DEK consistently localized to euchromatin 
[28, 30, 31]; however, knocking-down DEK in various cell types drastically reduces the 
distribution of heterochromatin [29, 32]. The later findings were further supported by the 
fact that DEK associates with heterochromatin binding protein (HP)1α allowing for binding 
to H3K9me3 and the chromatin remodeling complex B-WICH, both involved in the 
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replication and stabilization of heterochromatin [29, 33]. Information on the role of DEK in 
gene regulation is reviewed in detail in Sanden and Gulberg, 2015 [23**].
DEK undergoes several different post-transcriptional modifications that influence its activity. 
Phosphorylation of DEK is mediated by casein kinase 2 (CK2) in a cell cycle-dependent 
manner peaking in cells undergoing the G1 phase of the cell cycle [34]. Phosphorylation by 
CK2 reduces binding of DEK to histones and decreases the affinity of DEK binding to DNA 
[30, 34]. However, when DEK is unphosphorylated, it dimerizes and remains bound to 
chromatin [30]. Poly(ADP-ribosyl)ation of DEK by poly(ADP-ribose) polymerase (PARP)1 
also leads to its removal from chromatin and is associated with its accumulation during 
apoptosis [35, 36]. Phosphorylation and poly(ADP-ribosyl)ation of DEK are two possible 
mechanisms regulating whether DEK activates or suppresses gene expression. Acetylation 
of DEK can also reduce the ability of DEK to bind to DNA. This disruption is associated 
with the relocalization of DEK to RNA processing machinery where DEK plays a role in 
intron removal [37–40]; however, due to issues with the specificity of the DEK antibodies 
used in these studies the role of DEK in RNA processing remains controversial [23**].
Extracellular DEK
Both phosphorylation by CK2 and poly(ADP-ribosyl)ation by PARP1 of DEK removes it 
from chromatin [30, 34, 36, 41]. These post-transcriptional modifications led to one of the 
most surprising observations about DEK, its ability to be secreted by cells [32, 41]. DEK is 
passively secreted by cells undergoing apoptosis (a process associated with poly(ADP-
ribosyl)ation) and actively secreted by macrophages upon stimulation with interleukin (IL)-8 
in a Golgi-apparatus-independent manner either in a free form or within exosomes [41]. This 
process can be blocked by the immunosuppressants dexamethasone and cyclosporine A 
suggesting that DEK plays a role in inflammation. Secreted DEK both in its free-form (by 
acting as a chemoattractant for neutrophils, cytotoxic T lymphocytes, and natural killer cells) 
and in exosomes is associated with autoimmunity. Circulating auto-antibodies against DEK 
have been found in juvenile idiopathic arthritis (JIA), sarcoidosis, and systemic lupus 
erythematosus [41, 42]. In JIA, both DEK and DEK auto-antibodies have been found in 
synovial fluids [41]. It is hypothesized that the secreted DEK in exosomes fuses with the 
membrane of antigen presenting cells where DEK is processed and presented to B cells 
allowing for DEK auto-antibody production. These findings suggest an important role for 
DEK in autoimmune disease pathogenesis.
The fact that DEK can act as a chemoattractant for immune cells suggests that DEK can be 
recognized by a yet unidentified extracellular receptor; however, DEK can also penetrate 
cells [32, 41]. DEK is a bulky, charged, and hydrophilic protein that is unable to cross the 
plasma membrane by diffusion. DEK can bind to the negatively charged, translocatory 
protein heparan sulfate-type proteoglycan (HSPG) allowing DEK to be endocytosed via 
invaginations in the plasma membrane [32]. Once internalized DEK can relocate to the 
nucleus and perform its normal intracellular/exogenous activity.
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DEK and Hematopoiesis
Endogenous DEK and Hematopoiesis
DEK expression in human and mouse hematopoietic cells greatly changed with the level of 
maturity of the cell population. Upon examination of DEK mRNA levels in HSCs/HPCs and 
mature myeloid lineage cells, it was discovered that DEK expression was elevated in HSCs 
and HPCs when compared to mature granulocytic and monocytic populations in both human 
and mice [1, 43]. However, peak DEK expression levels varied between mice and man [1]. 
The greatest DEK expression in humans occurred in HSCs with a steady decline in 
expression levels as the cells differentiated into HPCs then matured into polymononuclear 
cells (PMNs) and monocytes. DEK expression levels were higher in monocytes then PMNs. 
In mice, DEK expression was greater in HPCs followed by HSCs, PMNs, and monocytes. 
Altered DEK expression levels during hematopoiesis indicate that DEK has specific 
functions in different cell types which may vary between humans and mice; however, this 
hypothesis requires further exploration.
To determine whether DEK regulates hematopoiesis, C57Bl/6 DEK−/− bone marrow was 
utilized to examine HSC/HPC numbers and function (see Figure 1A; [18, 19]). Increased 
numbers of colony forming units (CFU)-granulocyte monocyte (GM; granulocyte-monocyte 
progenitors), blast-forming unit-erythroid (BFU-E; erythroid progenitors), and CFU-
granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM; multipotent progenitors 
for myeloid cells) was seen using DEK−/− bone marrow when compared to wildtype bone 
marrow cells. Increases in DEK−/− bone marrow colony formation were associated with 
increased HPC cycling suggesting that DEK decreases HPC numbers by regulating 
proliferation. These findings were also seen in DBA DEK−/− bone marrow suggesting that 
the effect of DEK was not limited to the C57Bl/6 mouse strain [19]. C57Bl/6 DEK−/− bone 
marrow also demonstrated decreased long but not short-term repopulating capacity in a 
competitive bone marrow transplantation model when compared to transplantation using 
wildtype bone marrow [18]. This difference was further exasperated in secondary, non-
competitive bone marrow transplantation suggesting that DEK is important in the self-
renewal and long-term repopulating capacity of HSCs.
Further supporting the idea that DEK regulates hematopoiesis, especially during 
differentiation of myeloid cells, is the fact that DEK can form a complex with the 
transcription factor CCAAT enhancer binding protein (C/EBP)α [20]. Fetal liver cells from 
C/EBPα−/− mice demonstrate decreased granulocyte-monocyte progenitor (GMP) cell 
numbers with the inability of these cells to terminally differentiate into mature myeloid cells 
[44]. The decrease in GMPs seen in C/EBPα−/− mice is associated with an increase in the 
self-renewal capacity of HSCs and is partially restored with the reintroduction of C/EBPα 
[20, 45–48]. DEK is recruited specifically to chromatin with C/EBPα enhancing granulocyte 
colony-stimulating factor receptor 3 (GCSFR3) promotor activation [20]. Phosphorylation of 
serine 21 on C/EBPα inhibits DEK from forming a complex with C/EBPα ultimately 
disrupting C/EBPα driven, G-CSF-mediated granulocyte differentiation.
In addition to C/EBPα, DEK interacts with essential upstream enhancer elements of the 
erythroid Krüppel-like factor (EKLF) promoter enhancing EKLF expression [49]. EKLF is a 
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zinc finger transcription factor that plays a role in the global regulation of erythroid gene 
expression by binding to DNA and recruiting chromatin-remodeling proteins and histone 
modifiers such as DEK [49–52]. Although murine embryonic stem cells deficient in EKLF 
can produce erythroid colonies in vitro, colonies were poorly hemoglobinized and 
enucleated erythrocytes in these colonies contained numerous Heinz bodies, inclusions 
within red blood cells composed of denatured hemoglobin [53]. EKLF−/− erythrocytes in 
mice appeared to be short-lived [49, 53]. Therefore, if DEK is essential in regulating EKLF 
expression, then DEK may also regulate mature, healthy erythrocyte numbers. These 
findings correlate well with the observations made using the DEK−/− mouse model that DEK 
regulates the function of myeloid progenitor cells.
Extracellular DEK and Hematopoiesis
To examine the role of extracellular DEK in regulating hematopoiesis, recombinant human 
(rh) DEK was utilized in experiments in vitro [18, 19]. Bone marrow and low-density human 
cord blood cells when in culture with rhDEK demonstrated inhibited formation of CFU-GM, 
BFU-E and CFU-GEMM in a dose-response manner and decreased the number of cycling 
HPCs (see Figure 1B). The negative regulatory role of rhDEK on colony numbers and 
cycling status in both mouse and humans in vitro further supports the findings from the 
DEK−/− mouse model that DEK is required for the maintenance of HPC numbers whether 
intracellular or extracellular; however, the role of extracellular DEK in regulating HSCs 
remains unknown.
How extracellular/recombinant DEK regulates HPC numbers and function in mouse bone 
marrow cells or low-density human cord blood cells is not yet well understood. DEK may 
function through several different pathways. First, extracellular DEK may become 
internalized, as it is known to do in other cell types, by binding to HSPGs, translocating to 
the nucleus, and then binding to chromatin thus having regulatory effects on cell 
proliferation and transcription. Second, extracellular DEK may bind to a yet unknown 
receptor and mediate a signal transduction pathway. Third, DEK internalization may be 
receptor-mediated in hematopoietic stem/progenitor cells. Finally, DEK may be working 
indirectly through another cell in the bone marrow or cord blood low-density population 
altering the cytokine milieu. This last possibility seems unlikely, however, as the suppressive 
effects of rhDEK on colony formation were apparent even when assayed using single human 
CD34+ cord blood cells [18]. Thus far, DEK is only known to be actively secreted under 
inflammatory/stress-mediated conditions [32, 36, 41]; therefore, any effect that DEK has on 
the inflammatory or stress response may also regulate hematopoiesis.
DEK and Inflammation
DEK is associated with inflammation as demonstrated by its function in autoimmune 
diseases (as discussed above), persistent viral infections (e.g. human immunodeficiency 
virus and Kaposi’s sarcoma-associated herpesvirus [25, 54–57]), and tumorigenesis (for a 
comprehensive review on these topics please read Pease et al., 2015 [58**]). DEK secretion 
is induced in response to inflammatory stimuli and can be inhibited by the 
immunosuppressive agents [41]. DEK expression levels are also increased following 
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inflammatory stimuli. In vivo models where rodents ate diets containing organic pollutants 
demonstrated a significant increase in molecules persistent with chronic low-grade 
inflammation and in DEK expression [59, 60]. DEK expression levels were also increased in 
human bronchial epithelial cells exposed to fine particles found in industrial workplaces in 
an in vitro model of airway inflammation [61]. Although the mechanism is not clear why 
DEK expression increased following inflammation or whether using immunosuppressants 
can block this phenomenon, upon examination of the DEK promotor region several 
inflammation-associated transcription factor binding sites were found. These transcription 
factors include C/EBPβ, AP-1, Ets-1, NF-κB, STAT4, and NF-AT [58**]. Although not 
much is known about the relationship of most of these transcription factors and DEK, the 
interaction between DEK and NF-κB has been explored.
The NF-κB signaling pathway is a crucial pathway involved in inflammation and the 
immune response. Loss of DEK was associated with an increase in NF-κB activity [62–64]. 
Tumor necrosis factor (TNF)α-treated DEK−/− mouse embryonic fibroblast cells (MEFs) 
had increased NF-κB activity as indicated in a luciferase expression assay and had increased 
transcription of NF-κB target genes and increased NF-κB p65 (a subunit of NF-κB) 
translocation to the nucleus, an indicator of NF-κB activation [64]. Further studies in HeLa 
cells where DEK was silenced using shRNA demonstrated increased IκBα, an important 
NF-κB inhibitor, phosphorylation-induced degradation in association with increased NF-κB 
activity [62, 63]. These findings suggest that DEK is a negative regulator of NF-κB 
activation. However, the effect of DEK on NF-κB signaling is more complicated. In TNFα-
treated, non-manipulated HeLa cells, DEK co-localized with NF-κB p65 to the promotor 
regions of the NF-κB target genes, IL-8 and c-IAP2, increasing their mRNA expression 
levels [64]. Although not examined, this could potentially be a critical pathway in regulating 
DEK secretion from cells since, as previously mentioned, IL-8 induced DEK secretion by 
macrophages thus possible forming a feedback loop [41]. Under physiological conditions 
(normal to slightly elevated levels of DEK) DEK is associated with NF-κB activation via the 
degradation of the NF-κB inhibitor, IκBα [58**, 62, 63]. Further complicating matters, 
overexpression of DEK in HeLa cells inhibits NF-κB activity in a dose-dependent manner 
[62, 64]. These data put together suggests that the concentration of DEK within the cell 
plays a large part on whether or not DEK inhibits or activates NF-κB activity.
Conclusion
DEK regulates hematopoiesis by increasing the repopulating and self-renewal capacity of 
HSCs while decreasing HPC cycling and numbers; however, the molecular mechanisms of 
how DEK differentially regulates HSCs and HPCs remains unknown. Understanding how 
DEK regulates hematopoiesis under homeostatic conditions may lead to new methods of 
enhancing HSC numbers allowing for more efficient HSCT. This would also help us to 
understand how DEK may function under inflammatory and/or stress conditions. DEK, 
released extracellularly by immune cells following inflammatory stimuli and cell death, may 
act as a danger signal influencing inflammation/disease pathogenesis and ‘emergency’ 
hematopoiesis (see figure 2). Recently it has been shown that DEK-targeting DNA aptamers 
can reduce joint inflammation in an animal model of arthritis [65**]. Modulating DEK 
Capitano and Broxmeyer Page 6
Curr Opin Hematol. Author manuscript; available in PMC 2018 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
expression, secretion and/or function during hematopoiesis may be a potential target to 
modulate chronic inflammatory conditions thus augmenting disease pathogenesis.
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Key Points
• DEK, a protein abundantly found in the nucleus, plays an important role in 
both enhancing and repressing gene expression by altering chromatin 
structure.
• Endogenous DEK can regulate hematopoiesis by increasing the self-renewal 
and repopulating capacity of hematopoietic stem cells and by decreasing the 
cycling and number of hematopoietic progenitor cells.
• Inflammatory stimuli enhance DEK expression levels and its ability to be 
secreted extracellularly.
• Extracellular DEK functions as a chemoattractant for immune cells but also 
regulates hematopoietic progenitor cell cycling and numbers.
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Figure 1. 
Effects of endogenous/intracellular and extracellular DEK on hematopoiesis. (A) 
Endogenous/intracellular DEK decreases hematopoietic progenitor cell (HPC) numbers and 
inhibits HPC cycling while increasing the long-term competitive repopulation capacity in 
lethally irradiated congenic mice and increasing the repopulation of lethally-irradiated 
secondary mouse recipients in a non-competitive transplantation model indicating that 
endogenous DEK enhances hematopoietic stem cell (HSC) repopulating and/or self-renewal 
capability. (B) Extracellular DEK, as determine through the co-culture of either mouse bone 
marrow cells and/or low-density human cord blood cells with recombinant DEK, decreases 
HPC numbers and inhibits HPC cycling. The effect of extracellular DEK on HSC function is 
currently unknown.
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Figure 2. 
The possible role DEK may play during inflammation and how changes in DEK expression/
secretion regulate hematopoiesis. Inflammatory stimuli, such as IL-8, can lead to the 
secretion of DEK. Extracellular DEK is known to inhibit early myeloid progenitor cells; 
however, whether it can increase G-CSF-mediated granulocytic differentiation or alter 
hematopoietic stem cell function like endogenous DEK remains unknown. Hematopoietic 
cells (e.g. granulocytes) also migrate towards secreted DEK. The migration of mature 
hematopoietic cells into secondary tissues/blood will ultimately also influence 
hematopoiesis.
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